Latest HER2/neu Stories

(Ivanhoe Newswire) -- The American Cancer Society estimates there will be more than 200,000 new cases of invasive breast cancer in women and 39,000 deaths, this year alone. Other than skin cancer, breast cancer is the most common form of cancer for women in the United States. Any hope about how to fight these two cancers is highly useful. Now, two studies have shown that targeting a single protein can help fight both breast cancer and leukemia. Hsp90 is a specialized chaperone that assists...

Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent. In a report in the January 17 issue of The Lancet, an international research team reports that a protocol adding lapatinib (Tykerb) to trastuzumab (Herceptin) was more effective than single-drug treatment with either drug in eliminating microscopic signs of cancer at the time the tumors were surgically...

SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced that an audio rebroadcast of the presentation by its Chairman and CEO, James A. Joyce, at the Biotech Showcase(TM) 2012, on January 9, 2012, is now be available at: (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) http://www.media-server.com/m/p/dfvbu2du In addition,...

WORCESTER, Mass. and TORONTO, Jan. 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37. Positive interim Phase 2b clinical data from the study in HER-2 expressing breast cancer subjects (presented last month at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas) has lead to an earlier-than-expected advancement in...

WORCESTER, Mass. and TORONTO, Dec. 14, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that Bloomberg Television will air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. The story, expected to air December 19, 2011, will cover the Company's novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37), which is the subject of an ongoing Phase 2 clinical study in...

Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer with Herceptin, say Mayo Clinic researchers. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth. The finding, presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium,...

LOS ANGELES, Dec. 9, 2011 /PRNewswire/ -- Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma's investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas. These presentations are further detailed below: Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients...

Obese patients with early-stage HER2-positive breast cancer may have worse outcomes than patients who are normal weight or overweight, Mayo Clinic researchers found in a study presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth. "Not only did obese women have poorer outcomes given several different therapies tested to treat...

A large, multicenter, randomized study has shown that obese patients with HER2-positive breast cancer have larger tumors, increased lymph node involvement and, when not treated with trastuzumab, poorer long-term outcomes than normal-weight patients. This is the first time the relationship between obesity and HER2-positive breast cancer has been studied, according to Jennifer A. Crozier, M.D., a medical resident at Mayo Clinic, Jacksonville, who presented the results at the 2011 CTRC-AACR...

Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant. Luca Gianni, M.D., director of medical oncology at the San Raffaele Cancer Center in Milano, Italy, presented results from AVEREL, a randomized, phase 3 trial, at the 2011...